A comparison of olanzapine versus risperidone for the treatment of schizophrenia: A meta-analysis of randomised clinical trials

International Journal of Psychiatry in Clinical Practice

Volumn 9, Issue 1, 2005, Pages 3-15

  Mudge, Mia A C ^a   Davey, Peter J ^a   Coleman, Kristina A ^a   Montgomery, William ^b   Croker, Victoria S ^b   Mullen, Karen ^b   Castle, David J ^c  

^a M TAG   (Australia)

^b ELI LILLY AUSTRALIA PTY LTD   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antipsychotics; Efficacy; Meta analysis; Olanzapine; Risperidone

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 14944385641     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500510014783     Document Type: Review

References (60)

1. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. Br Med J 1998;317:1181-4.
2. Kane JM. Tardive dyskinesia in affective disorders. J Clin Psychiatry 1999;60(S5):43-9.
3. Moller HJ. Novel antipsychotics and negative symptoms. Int Clin Psychopharmacol 1998;13(S3):S43-7.
4. Moller HJ. Atypical neuroleptics: A new approach in the treatment of negative symptoms. Eur Arch Psychiatry Clin Neurosci 1999;249(S4):99-107.
5. Lima FB, Cunha RS, Costa LM, et al. Meta-analysis to evaluate the efficacy and safety of olanzapine compared to haloperidol in the treatment of schizophrenia: Preliminary findings. J Bras Psiquiatr 1999;48:169-75.
6. Cummins C, Stevens A, Kisely S. The use of olanzapine as a first and second choice treatment in schizophrenia. In: DEC report. Birmingham: West Midlands; 1998. p 1-29.
7. Duggan L, Fenton M, Dardennes RM, et al. Olanzapine for schizophrenia. Cochrane Database Syst Rev 2000, issue 1; Art. No. CD001359.
8. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
9. Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev 2000, issue 2; Art. No. CD000966.
10. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. Br Med J 2000;321:1371-6.
11. Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2000, Issue 3; Art. No. CD002306.
12. Cheine M, Wahlbeck K, Rimon R. Pharmacological treatment of schizophrenia resistant to first-line treatment: A critical systematic review and meta-analysis. Int J Psychiatry Clin Pract 1999;3:159-69.
13. Hunter RH, Joy CB, Kennedy E, et al. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2003, issue 2; Art. No. CD000440.
14. Streiner DL. The case of the missing data: Methods for dealing with dropouts and other research vagaries. Can J Psychiatry 2002;47:68-75.
15. Davis JM, Chen N, Click ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
16. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
17. Gureje O, Miles W, Keks N, et al. Olanzapine versus risperidone in the management of schizophrenia: A randomized double-blind trial in Australia and New Zealand. Schizophr Res 2003;61:303-14.
18. Sacristan JA, Gomez JC, Montejo AL, et al. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: Results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina. Clin Ther 2000;22:583-99.
19. Kasper S. Risperidone and olanzapine: Optimal dosing for efficacy and tolerability in patients with schizophrenia. Int Clin Psychopharmacol 1998;13:253-62.
20. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995;166:712-33.
21. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
22. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74.
23. Williams R. Optimal dosing with risperidone: Updated recommendations. J Clin Psychiatry 2001;62:282-9.
24. Heinrichs DW, Hanlon TE, Carpenter WT. The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10(3):388-98.
25. Wirshing DA, Marshall BD, Green MF, et al. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 1999;156:1374-9.
26. Decks J, Altman D, Bradburn M. Meta-analysis in context, 2nd ed. London: BMJ Publishing Group, 2001.
27. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: A double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999;25:721-9.
28. Schwanz TL, Nihalani N, Jindal S, Virk S, Jones N. Psychotic medication-induced obesity: a review. Obes Rev 2004;5:115-21.
29. Lambert TJR, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003;178:S67-70.
30. Lambert T, Pantelis C. Hares and tortoises: Differential neuroleptic-associated weight gain in the community. [Abstract.] 7th Biennial Australasian Schizophrenia Conference, 24-26 October 2002, Sydney, Australia.
31. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
32. Enas GG, Goldstein DJ. Defining monitoring and combining safety information in clinical trials. Stat Med 1995; 14:1099-111.
33. Von Frenckell R, Copp J, Essers H, Theeuwes A. Format/ content of overviews (integrated efficacy and safety report). Drug Info J 1995;29:503-5.
34. McEntegart DJ. Pooling in integrated safety databases. Drug Info J 2000;34:495-9.
35. Song F, Glenny AM, Altman DG. Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials 2000;21:488-97.
36. Prior C, Clements J, Rowett M. Atypical antipsychotics in the treatment of schizophrenia. Users' experiences of treatments must be considered. Br Med J 2001;322(7291): 924-5.
37. Taylor D. Atypical antipsychotics in the treatment of schizophrenia. Pragmatic considerations are important when considering which drug to prescribe. Br Med J 2001;322(7291):925.
38. Lee S. Atypical antipsychotics in the treatment of schizophrenia. Informed relationship between doctor and patient does not exist in many parts of the world. Br Med J 2001;322(7291):925-6.
39. Anderson I. Atypical antipsychotics in the treatment of schizophrenia. Users' views are important. Br Med J 2001;32(7291):926.
40. Rowsell R, Link C, Donoghue J. Atypical antipsychotics in the treatment of schizophrenia. Validity of dropout rates as proxy measure of tolerability is unknown. Br Med J 2001;322(7291):925.
41. Remington G, Kapur S. Atypical antipsychotics: Are some more atypical than others? Psychopharmacology 2000; 148:3-15.
42. Tamminga CA. "New" rather than "atypical". Psychopharmacology 2000;148:20-1.
43. Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. Bipolar Disorders 2000;2:261-8.
44. Conley R, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74.
45. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000;57:249-58.
46. Beasley CM, Hamilton SH, Crawford AM, et al. Group TOES. Olanzapine versus haloperidol: acute-phase results of the international double-blind olanzapine trial. Neuropsychopharmacology 1996;7:125-37.
47. Beasley CMJ, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
48. Altamura AC, Velona I, Curreli R, Bravi D. Olanzapine in the treatment of paranoid schizophrenia. Eur Neuropsychopharmacol 1999;9(S5):S297.
49. Tran PV, Lieh-Mak F, Chen RYK, et al. A double-blind comparison of the efficacy and safety of olanzapine versus haloperidol in the treatment of patients with schizophrenia from Hong Kong. Data on file.
50. Zhang F, Taylor C, Kurtz D, Tran P. Efficacy, safety and pharmacokinetics of olanzapine versus haloperidol in the treatment of Chinese patients with schizophrenia from Taiwan and Hong Kong. Data on file.
51. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996;16:38-44.
52. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-8.
53. Cavallaro R, Mistretta P, Cocchi F, et al. Differential efficacy of risperidone versus haloperidol in psychological subtypes of subchronic schizophrenia. Human Psychopharmacol Clin Exp 2001;16:439-48.
54. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993;26:121-4.
55. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40.
56. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305.
57. Liu SK, Chen WJ, Chang CJ, Lin HN. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: A trial of risperidone versus haloperidol. Neuropsychopharmacology 2000;22:311-9.
58. Messotten F. Risperidone versus haloperidol in the treatment of chronic psychotic patients: A multicentre double-blind study. Clinical research report. RIS-INT-2, 1991; N 85163 (unpublished data, Janssen).
59. Min SK, Rhee CS, Kim CE, Kang DY. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: A parallel group double-blind comparative trial. Yonsei Med J 1993;34:179-90.
60. Zhang XY, Zhou DF, Cao LY, et al. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: A randomised double-blind study. Int Clin Psychopharmacol 2001;16:325-30.